Trial Profile
Transition from intravenous Epoprostenol to Oral Selexipag in patients with pulmonary arterial hypertension: a single center experience
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Selexipag (Primary) ; Epoprostenol
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 13 Jul 2017 New trial record
- 24 May 2017 Results (n=4) presented at the 113th International Conference of the American Thoracic Society.